Nanomedicine for the treatment of Alzheimer's disease.
Alzheimer's disease affects more than 35 million people worldwide and this number is presumed to double by the year 2050. Currently, there is no efficient therapy for this disorder but a promising approach is represented by nanotechnology, easily multifunctionalizable devices with size in the order of billionth of meter. This review provides a concise survey on the nano-based strategies for Alzheimer's disease treatment, aiming at carrying drugs across the blood-brain barrier, in particular to target the metabolism of β-amyloid peptide, a pivotal player in this pathology.
Department of Health Sciences, University of Milano-Bicocca, via Cadore 48, 20900 Monza, Italy.
Maria
M
Gregori
Massimo
M
Masserini
Simona
S
Mancini
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000378:metabolism* / Q000648:ultrastructure; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism* / Q000473:pathology; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity / Q000648:ultrastructure; D066263:Protein Aggregation, Pathological / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D016229:Amyloid beta-Peptides
Alzheimer's disease; amyloid-β peptide; blood–brain barrier; nanomedicine; nanoparticles